May 29 – June 2, 2026
McCormick Place Convention Center
Chicago, IL
Booth #27059
Showcasing Our Latest Innovations at ASCO 2026
Heading to Chicago this month for ASCO 2026? We’ll meet you there: visit us at Booth #27059 and be among the first to learn about Caris’ newest innovations in precision medicine — including two brand new additions to our portfolio of comprehensive molecular profiling solutions:
Caris ChromoSeq™
Myeloid malignancies are complex; genetic testing doesn’t have to be. Using high-coverage Whole Genome Sequencing (WGS), Caris ChromoSeq replaces the genetic testing portion of the diagnostic workflow for myeloid malignancies, synthesizing multiple test results into one actionable, easy-to-read report.
Caris MI Clarity™
Treatment decisions in early-stage breast cancer have long been made without full visibility into long-term recurrence risk, but what if oncologists could have insight into both early and late distant recurrence risk from the very beginning? Caris MI Clarity, a new approach to prognostic assessment in early-stage breast cancer, provides that insight — right from the point of diagnosis.
Coming Soon: Presenting New Caris Life Sciences Research at ASCO
Caris and collaborators from leading cancer centers — including those within the Caris Precision Oncology Alliance® (POA®) — will collectively present 32 studies across 10 tumor types (plus pan-cancer analyses) at ASCO 2026. (Abstracts and full schedule to follow.)
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure® delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.